Suggested recent literature

Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.

These articles are not part of the database yet. Each one is a suggestion. The AI judged it from the title and abstract only and can be wrong. A curator reads the full paper, and only then is it added to CancerImmunoDB. A column on this page shows the curators' decision as soon as there is one.

How the list is made

  1. Search. For every year from 2021 to 2026, PubMed is searched for primary research on cancer drugs together with immune terms, and the 100 best matches of each year are taken. Every PubMed ID comes from PubMed itself, never from the AI.
  2. AI screening. Google Gemini reads each title and abstract and says whether the study tests a named anticancer drug and measures its effect on the immune system, the same scope as the database. In a first check, it marked 33 of 40 articles that curators had already accepted as likely relevant (and 1 as uncertain), and it rejected all 20 unrelated cancer articles.
  3. Curator check. Curators read each suggested paper in full and decide. Accepted papers are entered into the database with their doses, techniques and immune terms.

Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.

574articles screened
360likely relevant
11uncertain
203not relevant
0checked by a curator
0accepted into the database
YearScreenedLikely relevant
20269961
202510081
20249872
20239245
202210052
20218549

Browse the suggestions

Reset Download the full list (CSV)

360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).

PMIDYearArticleDrugsStudy typeCancer typeIn the databaseCurator status
34524861 2021 Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models. Science translational medicine Likely relevant Tests pharmacological serotonin depletion using fluoxetine and telotristat, and PD-1 blockade, evaluating CD8+ T cell influx and PD-L1 expression in murine models and cell lines. fluoxetine; telotristat; anti-PD-1 Mixed pancreatic and colorectal cancer fluoxetine 0/0/0; telotristat 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
34593432 2021 REIC/Dkk-3 Gene Therapy Induces Immunogenic Cell Death in a Mouse Model of Malignant Mesothelioma. Anticancer research Likely relevant The study experimentally tests Ad-REIC and anti-CTLA-4 antibody in cell lines and mouse models, measuring immunogenic cell death and immunological changes. Ad-REIC; anti-cytotoxic T-lymphocyte-associated protein 4 antibody Mixed malignant mesothelioma Ad-REIC 0/0/0; anti-cytotoxic T-lymphocyte-associated protein 4 antibody 0/0/0 Awaiting curator check
34624222 2021 Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell Likely relevant Examines microbiota modulation and immune checkpoint blockade in mice and human patients, measuring immune cell subsets and interferon production. immune checkpoint blockade (ICB) Mixed melanoma immune checkpoint blockade (ICB) 0/0/0 Awaiting curator check
34628702 2021 Programmed death (PD)-1/PD-ligand 1 blockade mediates antiangiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker. Cancer science Likely relevant Tests anti-PD-L1/PD-1 antibodies in syngeneic mouse models and human samples, measuring upregulation of CXCL10/11 chemokines. anti-PD-L1 Ab; anti-PD-1 Ab Animal lung carcinoma anti-PD-L1 Ab 0/0/0; anti-PD-1 Ab 0/0/0 Awaiting curator check
34653365 2021 Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer cell Likely relevant The study experimentally evaluates paclitaxel and atezolizumab treatment in patients and measures changes in immune cell subsets and dynamics using single-cell RNA and ATAC sequencing. paclitaxel; atezolizumab Patient triple-negative breast cancer paclitaxel 21/5/8; atezolizumab 0/0/4 Awaiting curator check
34686340 2021 Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell reports Likely relevant Tests anti-TREM2 monoclonal antibody therapy in mouse syngeneic and orthotopic ovarian tumor models and measures anti-tumor immunity and macrophage/T-cell modulation. anti-TREM2 monoclonal antibody; checkpoint inhibitor Animal solid tumors, ovarian cancer anti-TREM2 monoclonal antibody 0/0/0; checkpoint inhibitor 0/0/0 Awaiting curator check
34732412 2021 SLAMF7 and TREM1 Mediate Immunogenic Cell Death in Colorectal Cancer Cells: Focus on Microsatellite Stability. Anticancer research Likely relevant The study uses colorectal cancer cell lines to examine immunogenic traits and apoptosis when treated with anti-PD-1 drugs and TREM1 inhibitors. anti-PD-1; TREM1 inhibitors Cell line colorectal cancer anti-PD-1 14/36/0; TREM1 inhibitors 0/0/0 Awaiting curator check
34755131 2021 Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell reports. Medicine Likely relevant Patient cohort treated with neoadjuvant nivolumab, evaluating T cell receptor repertoire, clonal expansion, and immune cell signatures. nivolumab Patient oral cavity squamous cell carcinoma nivolumab 1/2/4 Awaiting curator check
34965422 2021 USP19 exacerbates lipogenesis and colorectal carcinogenesis by stabilizing ME1. Cell reports Likely relevant The study tests an ERK2 inhibitor and anti-PD-L1 antibody in mouse models and measures PD-L1 expression and immune-related factors. ERK2 inhibitor; anti-PD-L1 antibody Animal colorectal cancer ERK2 inhibitor 0/0/0; anti-PD-L1 antibody 0/1/0 Awaiting curator check
34975854 2021 PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer. Frontiers in immunology Likely relevant The study experimentally tests the PARP inhibitor pamiparib in vitro and in vivo and measures its effect on PD-L1 expression and CD8+ T cells in pancreatic cancer. pamiparib; PD-L1 blockers; anti-PD-L1/PD-1 drugs Mixed pancreatic cancer pamiparib 0/0/0; PD-L1 blockers 0/0/0; anti-PD-L1/PD-1 drugs 0/0/0 Awaiting curator check
← Previous Page 15 of 15